{"id":36839,"date":"2020-05-19T09:00:00","date_gmt":"2020-05-19T07:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/?post_type=press_release&p=36839"},"modified":"2023-09-06T16:28:07","modified_gmt":"2023-09-06T14:28:07","slug":"ipsen-annonce-la-publication-dans-advances-in-therapy-de-la-premiere-comparaison-indirecte-ajustee-par-appariement-entre-cabometyx-cabozantinib-et-le-regorafenib-dans-le-traitement-du-carcinom","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-publication-dans-advances-in-therapy-de-la-premiere-comparaison-indirecte-ajustee-par-appariement-entre-cabometyx-cabozantinib-et-le-regorafenib-dans-le-traitement-du-carcinom\/","title":{"rendered":"Ipsen annonce la publication dans Advances in Therapy de la premi\u00e8re comparaison indirecte ajust\u00e9e par appariement entre Cabometyx\u00ae (cabozantinib) et le r\u00e9goraf\u00e9nib dans le traitement du carcinome h\u00e9patocellulaire avanc\u00e9"},"content":{"rendered":"